Despite experiencing a 15.5% slump since its last earnings report, Bio-Techne Corp TECH is making strides in the bio-tech market. Crucial updates include launching a panel for hard-to-decipher carrier screening genes and collaborating with Oxford Nanopore Technologies. Moreover, TECH has expanded its portfolio by adding RNA chips for human and mouse transcriptome, advancing spatial biology. The company's ESR1 Mutation Monitoring Assay has also been released. Despite valuations being perceived as steep, Bio-Techne's markets remain attractive, revealing potential for growth.
Reports suggest substantial revenue growth from their Q2 2025 earnings call. TECH recently won a significant legal battle over antibody patent infringement in a German court. They have also secured strategic investment from SPEAR BIO and added Bio-Techne Corporation to Weitz Partners III Opportunity Fund's holdings. AI-powered development platforms and new distribution agreements suggest potential expansion. However, bearish perspectives note a 37% stock value loss for shareholders and several share cuts from various financial corporations. Despite this, Q4 2025 performed strongly, causing a spike in Bio-Techne's stock.
Bio-Techne Corp TECH News Analytics from Mon, 08 Apr 2024 07:00:00 GMT to Sat, 08 Mar 2025 00:14:00 GMT - Rating 2 - Innovation 7 - Information 8 - Rumor -3
